BeOne Medicines
BeOne Medicines is a global oncology company that discovers and develops innovative medicines intended to improve the lives of patients worldwide. The company markets BRUKINSA (zanubrutinib), a BTK inhibitor approved for B-cell malignancies.
Company Info
Sector:Antibodies
Headquarters:Cambridge, Massachusetts, United States
Founded:2010
Website:beonemedicines.us/
Upcoming Milestones & Key Dates
2026-07-15
Earnings
Q2 2026 Earnings Call
2026-Q3
PDUFA
BRUKINSA label expansion PDUFA
Clinical Development Pipeline
BRUKINSA (zanubrutinib)
Target: BTKTislelizumab
Target: PD-1BGB-A1217 (ociperlimab)
Target: TIGITRecent News
No recent news updates available for this company.
Leadership Team
John V. Oyler
Co-Founder, Chairman and CEO
Xiaobin Wu
President and Chief Operating Officer
Aaron Rosenberg
Chief Financial Officer
Careers & Job Openings